CJC-1295
A modified GHRH analog that provides sustained growth hormone release, often combined with Ipamorelin.
⚠ Research & Educational Use Only. CJC-1295 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Sustained, elevated GH levels over extended periods
- Enhanced muscle growth and protein synthesis
- Significant fat loss, particularly visceral fat
- CJC-1295 is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Sustained, elevated GH levels over extended periods
- Enhanced muscle growth and protein synthesis
- Significant fat loss, particularly visceral fat
- Improved recovery from exercise and injury
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with a significantly extended half-life compared to natural GHRH. It works by binding to the GHRH receptor in the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone. The DAC (Drug Affinity Complex) version of CJC-1295 further extends its half-life to approximately 8 days by covalently binding to albumin in the bloodstream, allowing for once or twice-weekly injections. Without DAC (Mod GRF 1-29), it requires more frequent dosing but produces a more natural pulsatile GH release pattern. CJC-1295 is most commonly combined with Ipamorelin for a synergistic effect on GH release.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on CJC-1295. See all Growth Hormone Secretagogues peptides for comparison.
Common Stacks
CJC-1295 is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
The classic GH stack: CJC-1295 raises baseline GH levels while Ipamorelin delivers clean, timed pulses without cortisol or appetite spikes.
CJC-1295 provides sustained GH elevation while Tesamorelin's full-length GHRH agonism adds proven visceral fat reduction data.
CJC-1295 drives GH release which stimulates IGF-1 production; stacking with exogenous IGF-1 LR3 amplifies downstream anabolic signalling.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
CJC-1295 DAC: 1–2 mg once or twice weekly. Mod GRF 1-29 (no DAC): 100 mcg per injection, 1–3 times daily. Always combined with Ipamorelin (100–300 mcg) for optimal results. Common stacking protocol: inject both simultaneously, 30 min before bed or morning on empty stomach.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute with bacteriostatic water. For DAC version: once weekly injection is sufficient. For Mod GRF 1-29: inject simultaneously with Ipamorelin for synergistic GH pulse. Allow 2 hours of fasting before injection for maximum GH release (insulin inhibits GH). Rotate injection sites.
Research Video
Explore Further
Quick Reference
Research Articles
- CJC-1295 Dosage Guide: Reconstitution, Injection Volume Tables, and Protocol Guide7 min read
- CJC-1295: Growth Hormone-Releasing Hormone Analogue Research7 min read
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.